Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 6, 2016, Pages 1451-1465

  Calza, Leonardo ^a   Colangeli, Vincenzo ^a   Manfredi, Roberto ^a   Bon, Isabella ^a   Re, Maria Carla ^a   Viale, Pierluigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; ETRAVIRINE; FIBRIC ACID DERIVATIVE; FOSAMPRENAVIR PLUS RITONAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AEROBIC EXERCISE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID METABOLISM; METABOLIC PARAMETERS; PATHOGENESIS; PATIENT MONITORING; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ADVERSE EFFECTS; CHEMICALLY INDUCED; DIET; DYSLIPIDEMIAS; EXERCISE; HIV INFECTIONS; PROCEDURES;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIET; DYSLIPIDEMIAS; EXERCISE; HIV INFECTIONS; HUMANS;

EID: 84973338743     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv494     Document Type: Article

References (138)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 388: 853-60.
2. Palella FJ, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
3. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
4. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000; 32: 111-23.
5. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007; 7: 787-96.
6. Holmberg SD, Moorman AC,Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-8.
7. Friis-Møller N, Sabin CA, Weber R et al. for the The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
8. Obel N, Thomsen F, Kronborg G et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44: 1625-31.
9. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl 2): S1-45.
10. 2013 American Heart Association (AHA)/American College of Cardiology (ACC) Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl 2): S76-99.
11. European AIDS Clinical Society. EACS Guidelines 8.0, October 2015. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
12. Gross PA, Barrett TL, Dellinger EP et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994; 18: 421.
13. Mujawar Z, Rose H, Morrow MP et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4: e365.
14. Shinohara E, Yamashita S, Kihara S et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997; 25: 1502-6.
15. Haugaard SB, Andersen O, Pedersen SB et al. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 2006; 55: 175-82.
16. van Wijk JP, Castro Cabezas M. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution. Int J Vasc Med 2012; 2012: 201027.
17. Jones R, Sawleshwarkar S, Michailidis C et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6: 396-402.
18. Dubé MP, Parker RA, Tebas P et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-18.
19. Doser N, Sudre P, Telenti A et al. Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr 2001; 26: 389-90.
20. Friis-Møller N,Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV-patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-93.
21. Glass TR, Ungsedhapand C,Wolbers M et al. Prevalence and risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7: 404-10.
22. Hejazi N, Rajikan R, Choong CL et al. Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a crosssectional survey. BMC Public Health 2013; 13: 758.
23. Young J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviralnaıve patients starting PI-and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10: 585-91.
24. Randell PA, Jackson AG, Boffito M et al. Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naıve HIV-type-1-positive men. Antivir Ther 2010; 15: 1125-32.
25. Chapman SJ, Woolley IJ, Visvanathan K et al. Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia. AIDS 2007; 21: 532-3.
26. Vrouenraets SM, Wit FW, Fernandez Garcia E et al. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naıve HIV-1-infected patients. HIV Med 2011; 12: 620-31.
27. Overton ET, Arathoon E, Baraldi E et al. Effect of darunavir on lipid profile in HIV-infected patients. HIV Clin Trials 2012; 13: 256-70.
28. Sension M, Deckx H. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors. AIDS Rev 2015; 17: 21-36.
29. Quercia R, Roberts J, Martin-Carpenter L et al. Comparative changes of lipid levels in treatment-naıve, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig 2015; 35: 211-9.
30. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activation. AIDS 2002; 16: 1587-94.
31. Liang JS, Distler O, Cooper DA et al. HIV protease inhibitors protect apolipoprotein B fromdegradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7: 1327-31.
32. Torriani M, Thomas BJ, Barlow RB et al. Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution. J Appl Physiol 2006; 100: 609-14.
33. Petit JM, Duong M, Duvillard L et al. LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy. Eur J Clin Invest 2002; 32: 354-9.
34. van Wijk JP, Cabezas MC, de Koning EJ et al. In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy. J Clin Endocrinol Metab 2005; 90: 3575-82.
35. Carr A, Samaras K, Chrisholm DJ et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998; 351: 1881-3.
36. Hu C, Oliver JA, Goldberg MR et al. LRP: a new adhesion molecule for endothelial and smooth muscle cells. Am J Physiol Renal Physiol 2001; 281: F739-50.
37. Zha BS, Wan X, Zhang X et al. HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. PLoS One 2013; 8: e59514.
38. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta 2006; 1757: 700-7.
39. Tarr PE, Taffé P, Bleiber G et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191: 1419-26.
40. Lazzaretti RK, Gasparotto AS, Sassi MG et al. Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART. ScientificWorldJournal 2013; 2013: 608415.
41. Egana-Gorrono L, Martinez E, Cormand B et al. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy. AIDS 2013; 27: 529-38.
42. Currier JS, Lundgren JD, Carr A et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118: e29-35.
43. Rasmussen LD, May MT, Kronborg G et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV 2015; 2: e288-98.
44. Lang S, Mary-Krause M, Cotte L et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24: 1228-30.
45. DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
46. Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.
47. Strategies for Management of Antiretroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-24.
48. Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228-38.
49. Jerico C, Knobel H, Calvo N et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37: 812-7.
50. Maggi P, Perilli F, Lillo A et al. Rapid progression of carotid lesions in HAART-treated HIV-1 patients. Atherosclerosis 2007; 192: 407-12.
51. De Saint Martin L, Vandhuick O, Guillo P et al. Premature atherosclerosis in HIV-positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 2006; 185: 361-7.
52. Volpe GE, Tang AM, Polak JF et al. Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr 2013; 64: 51-7.
53. Maggi P, Perilli F, Lillo A et al. An ultrasound-based comparative study on carotid plaques in HIV-positive patients vs. atherosclerotic and arteritis patients: atherosclerotic of inflammatory lesions? Coronary Artery Dis 2007; 18: 23-9.
54. Calza L, Verucchi G, Pocaterra D et al. Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. Int J STD AIDS 2009; 20: 683-9.
55. Currier JS, Kendall MA, Zackin R et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19: 927-33.
56. Mangili A, Gerrior J, Tang AM et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006; 43: 1482-9.
57. Lebech AM, Wiinberg N, Kristoffersen US et al. Carotid intima-media thickness in HIV patients treated with antiretroviral therapy. Clin Physiol Funct Imaging 2007; 27: 173-9.
58. Hsue PY, Hunt PW, Schnell A et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23: 1059-67.
59. Hulten E, Mitchell J, Scally J et al. HIV positivity, protease inhibitor exposure, and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 2009; 95: 1826-35.
60. Mavroudis CA, Majumder B, Loizides S et al. Coronary artery disease and HIV: getting to the HAARTof the matter. Int J Cardiol 2013; 167: 1147-53.
61. Dubé MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613-27.
62. Lundgren JD, Battegay M, Behrens G et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9: 72-81.
63. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-21.
64. European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769-818.
65. Law MG, Friis-Moller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 218-30.
66. Friis-Moller N, Thiebaut R, Reiss P et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491-501.
67. Schambelan M, Wilson PW, Yarasheski KE et al. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008; 118: e48-53.
68. Krikke M, Hoogeveen RC, Hoepelman A et al. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL), and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. HIV Med 2015; doi:10.1111/hiv.12300.
69. Zanni MV, Fitch KV, Feldpausch M et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS 2014; 28: 2061-70.
70. Jones SP, Doran DA, Leatt PB et al. Short-term exercise training improves body composition and hyperlipidemia in HIV-positive individuals with lipodystrophy. AIDS 2001; 15: 2049-51.
71. Yarasheski KE, Tebas P, Stanerson B et al. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol 2001; 90: 133-8.
72. Wooten JS, Nambi P, Gillard BK et al. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc 2013; 45: 1043-50.
73. Song W, Wang W, Dou LY et al. The implication of cigarette smoking and cessation on macrophage cholesterol efflux in coronary artery disease patients. J Lipid Res 2015; 56: 682-91.
74. Domingo P, Labarga P, Palacios R et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18: 1475-8.
75. Moyle GJ, Sabin CA, Cartledge J et al. A randomized, comparative trial of tenofovir DF or abacavir as replacement for thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
76. Gerschenson M, Kim C, Berzins B et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009; 63: 1244-50.
77. Campo R, DeJesus E, Bredeek UF et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/ tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013; 56: 1637-45.
78. Moyle GJ, Orkin C, Fisher M et al. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/ emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLoS One 2015; 10: eD116297.
79. Parienti JJ, Massari V, Rey D et al. for the SIROCCO Study Team. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis 2007; 45: 263-6.
80. Waters L, Fisher M, Winston A et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011; 25: 65-71.
81. Casado JL, de Los Santos I, Del Palacio M et al. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. HIV Clin Trials 2013; 14: 1-9.
82. Mills AM, Cohen C, Dejesus E et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/ tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials 2013; 14: 216-23.
83. Pinnetti C, Di Giambenedetto S, Maggiolo F et al. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: data from a multicenter cohort. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19812.
84. Gupta SK, Mi D, Moe SM et al. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr 2013; 64: 279-83.
85. Ucciferri C, Falasca K, Vignale F et al. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol 2013; 85: 755-9.
86. Lu CL, Lin YH, Wong WW et al. Outcomes of switch to atazanavircontaining combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. J Microbiol Immunol Infect 2011; 44: 258-64.
87. Nguyen ST, Eaton SA, Bain AM et al. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highlyactive antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy 2008; 28: 323-30.
88. Sension M, Andrade Neto JL et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 2009; 51: 153-62.
89. Stanley TL, Joy T, Hadigan CM et al. Effects of switching from lopinavir/ ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009; 23: 1349-57.
90. Negredo E, Paredes R, Bonjoch A et al. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. Antivir Ther 1999; 4 Suppl 3: 23-8.
91. Calza L, Manfredi R, Colangeli V et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidemia. AIDS 2005; 19: 1051-8.
92. Echeverria P, Bonjoch A, Puig J et al. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study. PLoS One 2014; 9: e84676.
93. Palella FJ, Fisher M, Tebas P et al. Simplification to rilpivirine/emtricitabine/ tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014; 28: 335-44.
94. Martinez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697-707.
95. Arribas JR, Pialoux G, Gathe J et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomized, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014; 14: 581-9.
96. Bonjoch A, Pou C, Perez-Alvarez N et al. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. J Antimicrob Chemother 2013; 68: 1382-7.
97. Reliquet V, Chirouze C, Allavena C et al. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antivir Ther 2014; 19: 117-23.
98. Casado JL, Banon S, Rodriguez MA et al. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviralmaintenance regimen in HIV-infected patients. Antiviral Res 2014; 113C: 103-6.
99. Monteiro P, Perez I, Laguno M et al. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother 2014; 69: 742-8.
100. Calza L. Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics. Drug Healthc Patient Saf 2009; 1: 25-33.
101. Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol 2014; 10: 51-65.
102. Palacios R, Santos J, Gonzalez M et al. Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 536-7.
103. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-9.
104. Bonnet F, Balestre E, Thiebaut R et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med 2004; 5: 133-9.
105. Benesic A, Zilly M, Kluge F et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004; 32: 229-33.
106. Visnegarwala F, Maldonado M, Sajja P et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004; 49: 283-90.
107. Hurlimann D, Chenevard R, Ruschitzka F et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart 2006; 92: 110-2.
108. Aberg JA, Zackin RA, Brobst SW et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Human Retroviruses 2005; 21: 757-67.
109. Mallon PW, Miller J, Kovacic JC et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS 2006; 20: 1003-10.
110. Normen L, Yip B, Montaner J et al. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. HIV Med 2007; 8: 346-56.
111. Rahman AP, Eaton SA, Nguyen ST et al. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. Pharmacotherapy 2008; 28: 913-9.
112. Calza L, Manfredi R, Colangeli V et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6: 572-8.
113. Aslangul E, Assoumou L, Bittar R et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010; 24: 77-83.
114. Calza L, Trapani F, Bartoletti M et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-a in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials 2012; 13: 153-61.
115. Calza L, Manfredi R, Colangeli V et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses 2013; 29: 547-56.
116. Eckard AR, Jiang Y, Debanne SM et al. Effect of 24weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209: 1156-64.
117. Feinstein MJ, Achenbach CJ, Stone NJ et al. A systematic review of statin therapy in HIV-infected patients. Am J Cardiol 2015; 115: 1760-6.
118. Egeland GM, Igland J, Sulo G et al. Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: Cohort Norway. Eur J Prev Cardiol 2014; 22: 872-81.
119. Stauffer ME,Weisenfluh L, Morrison A. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Vasc Health Risk Manag 2013; 9: 671-80.
120. Palacios R, Santos J, González M et al. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 251-3.
121. Badiou S, Merle De Boever C, Dupuy AM et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004; 172: 273-9.
122. Rao A, D'Amico S, BalasubramanyamA et al. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 2004; 327: 315-8.
123. Balasubramanyam A, Coraza I, Smith EO et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab 2011; 96: 2236-47.
124. Chang JT, Staffa JA, Parks M et al. Rhabdomyolysis with HMGCoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417-26.
125. Gerber MT, Mondy KE, Yerasheski KE et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004; 39: 419-25.
126. Dubé MP, Wu JW, Aberg JA et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006; 11: 1081-9.
127. Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr 2004; 36: 878-80.
128. Wohl DA, Tien HC, Busby M et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005; 41: 1498-504.
129. Carter VM, Woolley I, Jolley D et al. A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex Health 2006; 3: 287-90.
130. De Truchis P, Kirstetter M, Perier A et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr 2007; 44: 278-85.
131. Paranandi A, Asztalos BF, Mangili A et al. Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia. AIDS Res Hum Retroviruses 2014; 30: 800-5.
132. Peters BS, Wierzbicki AS, Moyle G et al. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Clin Ther 2012; 34: 67-76.
133. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-27.
134. Coll B, Aragonés G, Parra S et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006; 20: 1675-7.
135. Wohl DA, Waters D, Simpson RJ Jr et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008; 47: 1105-8.
136. Negredo E, Molto J, Puig J et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006; 20: 2159-64.
137. Chastain LM, Bain AM, Edwards KL et al. A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy-methylglutaryl-coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. J Clin Lipidol 2007; 1: 634-9.
138. Chow D, Chen H, Glesby MJ et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS 2009; 23: 2133-41.